Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 10

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 10
---
 we expect to file within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form 8-K within four business days after the Annual Meeting, we intend to file a Form 8-K to publish preliminary results and, within four business days after the final results are known to us, file an additional Form 8-K to publish the final results. “Smaller Reporting Company” Scaled Disclosure We qualified as a “smaller reporting company” for our fiscal year ended December 31, 2024, and as a result we are permitted to rely, and have relied, on exemptions from certain disclosure and other requirements that are applicable to other public companies, including exemptions that provide for reduced disclosure obligations regarding executive compensation for this proxy statement. These scaled disclosures will no longer be applicable or available to us beginning with our quarterly report on Form 10-Q for the three-month period ending March 31, 2025. 6 TABLE OF CONTENTS PROPOSAL 1 ELECTION OF DIRECTORS The Board is divided into three classes, with only one class of directors being elected in each year and each class, Class I, Class II and Class III, serving a three-year term. Each Class I director has a term that expires at this Annual Meeting, each Class II director has a term that expires at the Company’s 2026 annual meeting of stockholders and each Class III director has a term that expires at the Company’s 2027 annual meeting of stockholders, or in each case until their respective successors are duly elected and qualified, or until their earlier death, resignation, or removal. The Board currently has nine members. The current directors are Marshall Fordyce, M.D., Michael Morrissey, Ph.D., Andrew Cheng, M.D., Ph.D., Patrick Enright, Kimball Hall, Maha Katabi, Ph.D., Scott Morrison, Christy Oliger and Beth Seidenberg, M.D. There are three directors in the class whose term of office expires in 2025: Marshall Fordyce, M.D., Beth Seidenberg, M.D., and Kimball Hall. Each is currently a director of the Company and has previously been elected by the stockholders. If elected at the Annual Meeting, each of these nominees would serve until the Company’s 2028 annual meeting of stockholders and until the director’s successor has been duly elected and qualified, or, if sooner, until the director’s death, resignation or removal. It is the